PCOS Is a Metabolic Condition That Happens to Affect Ovaries

Polycystic ovary syndrome is the most common endocrine disorder in women of reproductive age, affecting somewhere between eight and thirteen percent depending on the criteria used. A large share of those women are undiagnosed.

Part of the reason is the name. It points at the ovaries, so the condition gets routed to reproductive care, and the metabolic engine underneath it goes unaddressed for years. Many of my patients were handed a birth control pill at nineteen and told to come back when they wanted to get pregnant. Nobody checked their insulin.

The mechanism, in order

For most women with PCOS, the sequence begins with insulin resistance.

Cells respond poorly to insulin, so the pancreas produces more of it. Elevated insulin then does three things in parallel.

It stimulates the theca cells of the ovary to produce more androgens, primarily testosterone. It suppresses sex hormone binding globulin production in the liver, and since SHBG is what keeps testosterone bound and inactive, less SHBG means more free testosterone even when total testosterone looks unremarkable. It also interferes with normal follicular development, so follicles begin to mature and then stall, which is what produces the appearance on ultrasound that gave the condition its name.

The visible results follow from that. Irregular or absent ovulation. Acne along the jawline and chin. Hair growth on the face, chest, or abdomen. Hair thinning at the crown in a male pattern. Weight that concentrates centrally and resists ordinary effort. Difficulty conceiving.

There is also an adrenal contribution in a subset of patients, reflected in elevated DHEA-S, and a genuine lean phenotype where body weight is normal and insulin resistance is still present at the tissue level. Assuming every woman with PCOS is overweight causes a great deal of missed diagnosis.

Getting the diagnosis right

The Rotterdam criteria require two of three features: irregular ovulation, clinical or biochemical evidence of excess androgens, and polycystic ovarian morphology on ultrasound. Other causes have to be excluded first, and that exclusion step is where workups most often fall short.

Thyroid disease, elevated prolactin, and non-classical congenital adrenal hyperplasia can all mimic PCOS. So can Cushing's syndrome, though it is rare. A proper evaluation checks TSH, prolactin, and 17-hydroxyprogesterone before landing on the diagnosis.

For the androgen picture I want total testosterone, free testosterone, SHBG, and DHEA-S. SHBG is the piece most often omitted, and it is frequently the most informative single value on the panel. A woman with total testosterone at the upper end of normal and an SHBG of 22 nmol/L has substantially more biologically active hormone than the total value suggests.

On the metabolic side I want fasting glucose, fasting insulin, A1c, and a full lipid panel. A two hour oral glucose tolerance test is worth doing in many patients, because women with PCOS carry meaningfully higher risk of impaired glucose tolerance and type 2 diabetes, and fasting values alone miss a portion of it.

If any of this sounds like your experience, you can book a virtual consultation with Dr. Sater to review your history and testing in full.

Ultrasound is helpful and it is not required when the other two criteria are clearly met. In adolescents, polycystic appearing ovaries are common enough to be unhelpful diagnostically.

What treatment should actually target

If insulin is upstream of the androgens, then improving insulin sensitivity addresses the cause rather than the symptoms.

Resistance training and regular walking improve insulin sensitivity independent of weight change, which matters enormously for lean patients and for anyone discouraged by the scale. Adequate protein, sufficient fiber, and attention to sleep all contribute. Modest weight reduction, in the range of five to ten percent, restores ovulation in a meaningful proportion of women who are carrying excess weight.

Metformin improves insulin sensitivity and often improves cycle regularity. Inositol comes up constantly and it is generally well tolerated. The evidence is weaker than the marketing suggests. The systematic review behind the 2023 international PCOS guideline found it limited and inconclusive, with only possible benefit for ovulation and inconsistent effects on metabolic markers. I treat it as an option to discuss rather than something I recommend.

GLP-1 receptor agonists have become genuinely useful in PCOS with obesity or significant insulin resistance, improving both metabolic parameters and, in many patients, ovulatory function. They require careful counseling around contraception and pregnancy planning, since fertility can return unexpectedly.

Combined oral contraceptives regulate bleeding, protect the endometrium, and reduce androgenic symptoms. They are a legitimate and useful treatment. They also do not address insulin resistance, and prescribing one without ever evaluating metabolic status is where a lot of care goes wrong. Anti-androgens such as spironolactone can be added for hirsutism and acne with appropriate contraception.

For fertility, letrozole is now first line for ovulation induction, having outperformed clomiphene for live birth rates in this population.

The part that gets left out

Endometrial protection matters. Cycles longer than about ninety days leave the endometrial lining under unopposed estrogen for extended periods, and long term that raises endometrial cancer risk. This needs an active plan rather than being ignored because pregnancy is not currently a goal.

Long term metabolic screening matters too. PCOS carries elevated lifetime risk of type 2 diabetes, dyslipidemia, hypertension, non-alcoholic fatty liver disease, and obstructive sleep apnea. Annual metabolic review is reasonable, and screening for sleep apnea is worth considering in anyone with the relevant symptoms.

And the psychological burden is real. Rates of depression and anxiety are meaningfully higher in this population, and the visible symptoms of the condition, hair growth, acne, hair loss, weight, land directly on how women experience themselves. That belongs in the treatment plan rather than at the edge of it.

What I want women with PCOS to know

You were likely given a diagnosis about your ovaries. What you actually have is a whole body metabolic condition, and treating the metabolism is what tends to improve everything downstream of it, including the ovaries.